|Articles|April 7, 2023

Pharma USA 2023: What Medicare Reform Means to Patient Access Network Foundation

Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes that impact Medicare, as well as the Foundation's near-term goals.

Kevin Hagan, president and CEO of the PAN Foundation, participated on the Pharma USA 2023 panel "Post-Inflation Reduction Act: The continued need for patient assistance." Here he speaks to Pharmaceutical Executive about the IRA's impact on how the Foundation will address its near- and longer-term goals.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

stock.adobe.com drug pricing

October 21st, 2026

Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds

Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.

John Stanford

October 21st, 2026

The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals

Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.

John Stanford

October 20th, 2026

How MFN Deals May Impact Future Decisions

Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.

stock.adobe.com ADC

October 19th, 2026

Hansoh Pharma Enters $15 Billion Collaboration and License Agreement with Roche

Hansoh Pharma enters a collaboration and license agreement with Roche covering a broad portfolio of antibody-drug conjugate programs.

Your Questions Answered

October 19th, 2026

Your Questions Answered: Foundayo’s EU Panel Backing, Enspryng for TED, Gilead’s Masked TCE Bet, FDA’s Rare Disease Overhaul, and More

Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim CEO — explained.

John Stanford

October 19th, 2026

Is Participation in MFN Voluntary?

Incubate’s John Stanford on why MFN deals are voluntary in name only — and why the leverage looks a lot like the IRA’s 95% excise tax.

Loss of exclusivity, biosimilar competition, and Maximum Fair Price are converging on medical benefit pricing in ways the industry has never had to model before. Credit: Stock.Adobe.com/Rawpixel.com

October 16th, 2026

The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble

Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.

John Stanford

October 16th, 2026

The Unique Considerations Mid-Sized Pharma Companies Face When Making MFN Deals

Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.

Trending on PharmExec

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

CSL Names Deborah Waterhouse as CEO and Manager Director

Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds

The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals